-+ 0.00%
-+ 0.00%
-+ 0.00%

Fulcrum Q1 FY26 net loss widens to $18.9 million; cash drops to $333.3 million

PUBT·04/27/2026 11:06:57
Listen to the news
Fulcrum Q1 FY26 net loss widens to $18.9 million; cash drops to $333.3 million
  • Fulcrum Therapeutics posted a Q1 2026 net loss of USD 18.9 million, or USD 0.25 per share.
  • Operating loss widened to USD 22.2 million.
  • Research and development expense climbed to USD 14.1 million due to higher employee compensation costs, including increased stock-based compensation.
  • Cash, cash equivalents, and marketable securities fell to USD 333.3 million.
  • Fulcrum reiterated cash runway into 2029 as it plans a potential registration-enabling trial for sickle cell candidate pociredir in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270700PRIMZONEFULLFEED9696730) on April 27, 2026, and is solely responsible for the information contained therein.